June 14, 2026 07:59 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tragedy in the skies: Five IAF personnel killed in AN-32 crash in Assam | 'Ask probe officers whether I hid anything': Abhishek Banerjee hits back after pre-dawn police search | Police storm Abhishek Banerjee's house at 3 am tracking aide, Mamata arrives; seizure list says 'NIL' | Big boost for India's security: DRDO successfully tests advanced missile shield | Indian-origin man jailed for 34 years in UK over horrific kidnap, torture and rape case | Mamata's nightmare deepens! Saayoni Ghosh, Dev, Rachana Banerjee among 19 rebel MPs seeking TMC split | Trump claims US 'ended war with Iran', Tehran yet to confirm a deal | Heartbreak for Indian sports: Manu Bhaker's mentor Jaspal Rana passes away at 49 | Three Indian seafarers, missing after US strike on tanker near Oman, confirmed dead | 'Choose your side': TMC MP Kalyan Banerjee's ultimatum to Mamata in open revolt against Abhishek
UK COVID19
Pixabay

UK testing new drug to prevent COVID-19 development after Coronavirus contraction: Reports

| @indiablooms | Dec 26, 2020, at 02:33 pm

Moscow/Sputnik: UK scientists are testing a new drug to prevent people, who have been exposed to the coronavirus, from falling ill with COVID-19, media reported.
 

According to The Guardian, the antibody therapy has been developed by the University College London Hospitals and the AstraZeneca pharmaceutical company.

“If we can prove that this treatment works and prevent people who are exposed to the virus going on to develop Covid-19, it would be an exciting addition to the arsenal of weapons being developed to fight this dreadful virus,” virologist Catherine Houlihan, who is leading the study, said, as quoted by The Guardian.

The drug will provide patients with an immediate cocktail of antibodies that may protect them from COVID-19 for 6-12 months.

The medicine may be used as an emergency treatment both to hospital inpatients and care home residents.

The therapy may be also useful for those, who had contact with COVID-19 patients, and students, who live, study and socialize in big communities.

If approved, the drug will be available for public use in March or April.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.